Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor. Despite aggressive multimodal chemo- and radiation therapy, median survival remains less than two years. Over the last years, it has become clear that glioma-specific, self-renewing cancer stem cells [Glioma Stem Cells (GSC)] are critical for initiation and therapeutic resistance of GBM. Therapeutic targeting of GSCs is thus considered a promising avenue to treat GBM. Here, we propose to directly examine cellular translation in GSCs. This critical aspect of gene regulation is poorly understood in GSCs. Yet, deregulation of translation is associated with oncogenesis in other tumors. We will use ribosome profiling to examine GSCs and differentiated glioma cells (DGCs) from patient-derived xenografts (PDXs). Preliminary data demonstrate the feasibility of this approach and show that protein production in GSCs is controlled to a significant degree at the level of translation. Based on these data, we hypothesize that translational control is a major determinant of the stem-like state of GSCs, and that ribosome profiling of PDXs can guide the identification of novel, GSC-specifc therapeutic targets. Our proposal aims to globally identify translationally regulated genes in GSCs and to delineate regulatory nodes that determine protein production in GSCs. We will utilize this insight to identify novel, GSC-specific therapeutic targets for GBM treatment, using shRNA on a panel of identified genes. The proposed work is expected to provide new insight into GSC biology, and identify new GSC-specific therapeutic targets. We anticipate obtained data to guide precision medicine strategies for GBM treatment.

Public Health Relevance

Glioblastomas, the most common and lethal brain cancer, contain Glioma Stem Cells that are highly resistant to conventional therapies. Therapeutic targeting Glioma Stem Cells is thought to be a promising new avenue to treat Glioblastoma, but effective therapeutic targets are needed. To indentify novel therapeutic targets, we will examine the regulation of protein production in Glioma Stem Cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS108093-01A1
Application #
9745131
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Fountain, Jane W
Project Start
2019-04-15
Project End
2021-03-31
Budget Start
2019-04-15
Budget End
2021-03-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106